tracken
Johnson & Johnson Aktie News
Positiv
Fast Company
●
12 Tage alt
Johnson & Johnson on Tuesday raised its 2025 sales forecast after reporting quarterly earnings that topped Wall Street expectations, and announced plans to spin off its orthopedics business into a standalone company.
Positiv
The Motley Fool
●
12 Tage alt
Johnson & Johnson (JNJ -0.02%) is one of the world's best dividend stocks. The healthcare giant has increased its dividend payment for 63 consecutive years.
Neutral
Seeking Alpha
●
13 Tage alt
Johnson & Johnson (NYSE:JNJ ) Q3 2025 Earnings Call October 14, 2025 8:30 AM EDT Company Participants Darren Snellgrove - Vice President of Investor Relations Joaquin Duato - CEO & Chairman Joseph Wolk - Executive VP & CFO Jennifer Taubert - Executive VP & Worldwide Chairman of Innovative Medicine Tim Schmid - Executive VP & Worldwide Chairman of MedTech John Reed - Executive Vice President of ...
Positiv
24/7 Wall Street
●
13 Tage alt
Finding top dividend stocks to invest in is one thing. Finding companies that can pay that dividend for years, and potentially decades, to come is a whole other story.
Neutral
Schaeffers Research
●
13 Tage alt
Johnson & Johnson (NYSE:JNJ) stock is down 1.2% to trade at $188.54 at last glance, brushing off an earnings and revenue beat for the third quarter.
Positiv
Proactive Investors
●
13 Tage alt
Johnson & Johnson (NYSE:JNJ) posted third-quarter revenue and earnings that beat Wall Street estimates, driven by strength in its pharmaceuticals and medical devices businesses. The healthcare giant reported revenue of $23.99 billion for the quarter, up 6.8% from a year ago and slightly above analysts' expectations of $23.74 billion.
Positiv
Seeking Alpha
●
13 Tage alt
Today, Johnson & Johnson released its financial results for Q3 2025, which once again stunned Wall Street. So, sales of Rybrevant/Lazcluze, the 'diamond' in its oncology franchise, reached $198 million, up 122.5% from Q3 2024. JNJ increased its 2025 reported sales guidance from $93.2-$93.6 billion to $93.5-$93.9 billion.
Positiv
Invezz
●
13 Tage alt
Johnson & Johnson on Tuesday lifted its 2025 revenue guidance after posting stronger-than-expected third-quarter earnings and revealed plans to spin off its orthopedics business into a standalone company, its second major separation in two years. The New Jersey-based healthcare conglomerate said it now expects product revenue between $93.5 billion and $93.
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
